top of page
ANVISA Approves Merck's Winrevair for PAH in Brazil | ANVISA Drug Approvals | Aprovações de medicamentos da ANVISA | iPharmaCenter
Winrevair (sotatercept) has been approved for treating adults with pulmonary arterial hypertension (PAH), classified under World Health...

Brazil April 2024 Drug Approvals | ANVISA | News | Media | iPharmaCenter
16, April 2024 Rybrevant is approved in Brazil for locally advanced or metastatic non-small cell lung cancer Rybrevant (amivantamab) is...


Brazil Healthcare News | Notícias de saúde no Brasil | notícias do Brasil | Atualizações | Updates | 2024 | iPharmaCenter
Brazilian Health Ministry Decided to Use Unspent R$17 billion ($3.4 billion) Which was Not utilized During COVID-19 Period Approximately...
ANVISA Drug approvals | Brazil drug approvals | January 2024 | iPharmaCenter
January 09, 2024 Recombinant COVID-19 vaccine is approved by ANVISA in Brazil to prevent COVID-19 infection Designed for the immunization...


Brazil Healthcare News, Pharma News | Drug approved in Brazil | iPharmaCenter
Ondexxya is prescribed for patients undergoing treatment with FXa inhibitors such as apixaban or rivaroxaban when there is an urgent need...
bottom of page